Taiwan-based Lotus Pharmaceutical Co. has announced a strategic licensing and commercialisation agreement with Alvotech, covering two of Alvotech’s candidates in the United States (US) and selected Asian markets: AVT34, a proposed biosimilar to Imfinzi® (durvalumab), and AVT87, a proposed biosimilar to Hemlibra® (emicizumab).
Imfinzi® is an oncology biologic used in the treatment of multiple cancers, which generated global sales of approximately $6.1 billion in 2025. Hemlibra® is a biologic for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with hemophilia A that generated global sales of approximately CHF4.8 billion in 2025, equivalent to approximately $5.8 billion.
In the United States, Lotus will commercialise both products under a semi-exclusive arrangement with Alvotech, which will retain the right to commercialise the products directly. Alvotech will retain responsibility for product development and for obtaining and maintaining marketing authorisations in the United States, and will serve as the exclusive supplier of the products across all markets covered by the agreement.
In Asia, Lotus will have exclusive commercialisation rights in eight selected markets: South Korea, Taiwan, Thailand, Vietnam, the Philippines, Singapore, Hong Kong and Malaysia. Lotus will be responsible for local regulatory submissions and commercialisation in these markets.
